1. In Vivo
  2. >>Innovation

Twist Bioscience: DNA Research Tools Put Fresh Spin On Drug Discovery

 
• By William Looney

Speed and efficiency are fundamental to the success of today’s biopharmaceutical enterprise, but the hunt is still on for transformative technologies to boost pipeline productivity and growth. One answer may lie in the arrival of replicable, synthetic versions of DNA.

IV1810_Twist_671281048_1200.jpg
Answers may lie in the arrival of replicable, synthetic versions of DNA • Source: Shutterstock

Speed and efficiency – from discovery to approval to market and beyond – are fundamental to the success of today’s biopharmaceutical enterprise. Making decisions faster and introducing efficiencies at every stage of the drug development cycle is now accepted dogma, but the search continues for something more transformative to boost pipeline productivity and growth.

One answer may lie in the arrival of replicable, synthetic versions of DNA, the design atelier behind the most cost-effective,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

More from In Vivo

Wide Of The Mark: ‘The Worst EU Medtech Predictions Have Not Come True’

 
• By Ashley Yeo

Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By Jo Shorthouse

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy